Trial Profile

A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-Week Cycle in Patients With Advanced Malignancies.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pracinostat (Primary) ; Azacitidine
Indications Haematological malignancies; Hodgkin's disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; Biomarker

Most Recent Events

25 Aug 2017 Results published in the Cancer.
02 Dec 2014 Results from the phase I portion in elderly patients with acute myeloid leukaemia published in an MEI Pharma media release.
19 Dec 2012 Results from the phase II part in patients with myelodysplastic syndromes were presented at the 54th Annual Meeting of the American Society of Hematology according to a MEI Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com